Результаты поиска

Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.

BACKGROUND: Switching between first-line disease-modifying therapies in patients with clinically stable relapsing-remitting multiple scleros … r (1) stayed on injectable platform therapy (interferon-β or glatiramer acetate) or (2) switched to dimethyl fumarate (DMF) or teriflunomide (TFL) and compared treatment outcomes using propensity-score-based methods and marginal structural models (MSM). RESULTS: We included 3206 patients in the study. We found no change in risk of 6-month confirmed Expanded Disabi …

Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.

Background High efficacy disease modifying therapies (DMT) in the management of Multiple Sclerosis (MS) have a favorable effect on relapse r … umab is the most commonly associated DMT linked to PML, followed by fingolimod and others including dimethyl fumarate, ocrelizumab, alemtuzumab. Among the different treatments used, no therapeutic agent was found to be superior in improving post-PML EDSS. Conclusions Younger age and lower JCV viral load at the time of PML diagnosis were associated with better outco …

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

OBJECTIVE: To develop recommendations for disease-modifying therapy (DMT) for multiple sclerosis (MS). METHODS: A multidisciplinary panel d … ukoencephalopathy risk in people with MS using natalizumab, fingolimod, rituximab, ocrelizumab, and dimethyl fumarate; and made suggestions for future research to evaluate relative merits of early treatment with higher potency DMTs vs standard stepped-care protocols, DMT comparative effectiveness, optimal switching strategies, long-term effects of DMT use, definiti …

An update on new and emerging therapies for relapsing-remitting multiple sclerosis.

Disease-modifying therapies (DMTs), known to actively reduce relapses and delay disability progression, have been used for the treatment of … ently, 2 new oral DMTs received FDA approval for the treatment of RRMS: teriflunomide (Aubagio) and dimethyl fumarate (Tecfidera). In addition, oral laquinimod, several monoclonal antibodies (eg, alemtuzumab, daclizumab, and ocrelizumab), and other agents have shown preliminary beneficial results in relapsing MS in phase 3 clinical trials. These new and emerging DM …

Incidence of Progression Independent of Relapse Activity (PIRA) under platform disease-modifying treatment in multiple sclerosis.

BACKGROUND: Comparative data on the impact of platform disease-modifying therapies (DMTs) on Progression Independent of Relapse Activity (PIRA) in patients with remitting-relapsing MS (RRMS) are limited. We compared the risk of PIRA among RRMS patients treated with oral (dimethyl fumarate [DMF] versus teriflunomide [TER]) and injectable (interferon beta [IFN] versus glatiramer acetate [GA]) therapies in a real-world setting. METHODS: We conducted a retrospective study including RRMS patients from the Italian MS Registry treated for ≥ 5 years with DMF, TER, IFN, or GA. PIRA was defined as conf…

Unlocking Sulforaphane's Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons.

AIMS: Friedreich ataxia (FRDA) is a neurodegenerative disorder typically caused by autosomal recessive inheritance of expanded guanine-adeni … induced pluripotent stem cells (iPSCs) with 550 GAA1 repeats (FA2). Here, we compared SF, Omav, and dimethyl fumarate (DMF) treatment in sensory neurons derived from three patient iPSC lines with varying GAA1 repeats: FA1 (867), FA2, and FA3 (450). RESULTS: In FA1, SF treatment improved cell viability and reduced oxidative stress and inflammation. In FA3, SF incre …

Profiling peripheral blood oxidative stress in multiple sclerosis.

BACKGROUND: Oxidative stress is implicated in the pathophysiology of multiple sclerosis (MS), but the potential of oxidative stress response … 11 primary progressive MS (PPMS) & 14 secondary progressive MS (SPMS)) were included; 12 commenced dimethyl fumarate (DMF), 12 ocrelizumab and 7 natalizumab. NFE2L2 (nuclear factor erythroid 2-related factor 2; Nrf2), CAT (catalase) and GPX1 (glutathione peroxidase 1) expression were downregulated in SPMS, with increased concentration of end products of oxidation. …

Advancements in Pharmacotherapy and Mobile Health Applications for Self-Management in Multiple Sclerosis: A Comprehensive Review.

INTRODUCTION: Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system, affecting nearly three m … amer acetate showed approximately 30% ARR reduction with excellent safety. Oral agents (fingolimod, dimethyl fumarate, teriflunomide, cladribine) achieved 45-55% ARR reduction and markedly better adherence, though periodic laboratory monitoring was required. Monoclonal antibodies (natalizumab, ocrelizumab) reached up to 68% relapse reduction, representing the highe …

Extensive peripheral immunoglobulin repertoire analyses in people with multiple sclerosis reveal disease-specific signatures and distinct treatment effects of disease modifying drugs.

BACKGROUND: B cells are crucial players in the pathogenesis of multiple sclerosis (MS), however, limited information is available on peripheral immunoglobulin (Ig) repertoires of people with MS (pwMS) in comparison to healthy individuals and during different treatments. METHODS: Next generation sequencing of Ig heavy chains (VH) originating from bulk-sorted B cell populations was performed in 33 pwMS and ten healthy controls. All 33 pwMS were examined longitudinally at baseline and six months after treatment with ozanimod, fingolimod, dimethyl fumarate, teriflunomide, cladribine or natalizumab…

Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination.

Multiple sclerosis (MS) has conventionally been considered a prototypical autoimmune disorder. While modern immunotherapies effectively cont … ronic neuroinflammation and obstructing repair processes. Established multiple sclerosis therapies, dimethyl fumarate and teriflunomide, exhibit direct, previously unrecognized metabolic effects, validating this pathway as therapeutically viable. Emerging strategies intentionally target these vulnerabilities: glutaminase inhibitors to counteract pathogenic Th17 cel …

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.

Epstein-Barr virus (EBV) infection has long been associated with the development of multiple sclerosis (MS). Patients with MS have elevated … ated MHC-I-restricted EBV-specific TRB sequence matches. Therapy with ocrelizumab, teriflunomide or dimethyl fumarate reduced EBV-specific, but not CMV-specific MHC-I-restricted TRB sequence matches. Together, these data suggest that the aberrant MHC-I-restricted T-cell response directed against EBV is specific to MS with regard to neuromyelitis optica, MOGAD and S …

Варианты лечения под воздействием болезней при очень раннем многоразовом склерозе - какие варианты имеются для включения под действием 5 Годы? Систематический обзор.

Фон/задачи: Очень ранний педиатрический множественный склероз (POMS) встречается редко; клинические исследования с использованием методов коррекции заболеваний (DMT) не проводились. Клинические работники полагаются на исследования, проводимые в пожилом возрасте. Этот обзор стал результатом трудностей, с которыми сталкиваются врачи, и несанкционированного использования ДМТ в этом возрасте. Методы: Обзор литературы исследований, проведенных в период между 1982 и 2025 на очень раннем этапе ПОМС, особенно с наступлением до достижения возраста 5, был выполнен в поисках результатов без DMT или без D

Совпадение в аннотации оригинала
Background/Objectives: Very early pediatric-onset multiple sclerosis (POMS) is rare; clinical studies using disease-modifying treatments (DM … eated, acute steroid therapy was administered; 11 received the DMTs interferon, Glatiramer acetate, Dimethyl fumarate, and Azathioprine (three), with only two high-efficacy therapies (Natalizumab and Rituximab). Our patient had partial remission under interferon, relapses when stopped and replaced by immunoglobulin and 9 years relapse-free interval when Natalizumab …

Анализ затрат и затрат на ранний и поздний период использования натененизумаба в высокоактивных релапсирующих множественных склерозах: имитационное исследование.

Натальизумаб (NAT) представляет собой установившуюся терапию для изменения заболеваний (DMT) для высокоактивного множественного склероза (MS). Однако его использование сопряжено со сложным процессом принятия решений, что зачастую приводит к первоначальному использованию методов лечения с низкой эффективностью. Недавно был утвержден первый биоаналогичный НАТ, что позволило обеспечить конкурентное ценообразование. В рамках этого исследования была проведена оценка социальных последствий инициирования НАТ в различных сценариях на основе анализа затрат и затрат. МЕТОДЫ: А 10-year Была использована

Совпадение в аннотации оригинала
BACKGROUND: Natalizumab (NAT) is an established disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, its use … s and 70% females. NAT was compared to common initial therapies (glatiramer acetate, teriflunomide, dimethyl fumarate, and fingolimod). Scenarios included continuous use, early (after 1 year), and delayed (5 years) switch to NAT. Baseline characteristics and probabilities for clinical and economic outcomes were derived from clinical trial data, published literature …

Серологический скрининг и обновление вакцин в группе пациентов с множественным склерозом в качестве стратегии предотвращения возобновления инфекции во время иммунодепрессантной терапии.

ВВЕДЕНИЕ: Серологическое обследование и вакцинация играют решающую роль в предотвращении инфекционных осложнений у пациентов с множественным склерозом (МС). Стандартизация тестов и протоколов вакцинации имеет важное значение для пациентов, проходящих курс лечения. ЦЕЛЬ: Данное исследование было направлено на оценку подверженности инфекционным заболеваниям путем проведения серологических тестов и обновления вакцин для пациентов, страдающих MS. МЕТОДЫ: В период с февраля 2021 года по июнь 2023 года неврологическая служба Метрополитического университета Сантоса провела перекрестное исследование п

Совпадение в аннотации оригинала
INTRODUCTION: Serological screening and vaccination play a crucial role in preventing infectious complications in patients with Multiple Scl … rmed for 64 (53.8 %) patients. MS treatments included: Glatiramer Acetate, Natalizumab, Fingolimod, Dimethyl Fumarate, Ocrelizumab and cladribine (Cladribine) and corticoid for MS flare-ups. Seroprevalence was: 66.0 % for the JC virus, 61.4 % Toxoplasmosis, 50.9 % Mononucleosis, 84.5 % Cytomegalovirus, 85.4 % Measles, 72.2 % Mumps, 92.6 % Rubella, and 94.2 % Varice …

Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey.

BACKGROUND AND OBJECTIVES: Available disease-modifying therapies (DMTs) for multiple sclerosis (MS) are rapidly expanding; although escalati … MS specialists). The most selected agents overall were fingolimod (14.7%), natalizumab (15.5%), and dimethyl fumarate (20.9%). Two-thirds of respondents indicated they would request contrast-enhanced surveillance MRI. DISCUSSION: Although there is a slight preference for initiating high-efficacy DMT at the time of initial MS diagnosis, opinions regarding the most …

Оптимизация выбора наркотиков у детей с множественным склерозом: что мы знаем и что остается без ответа?

Множественный склероз педиатрии (POMS) означает множественный склероз с наступлением в возрасте до 18 лет. Она характеризуется более подстрекательским курсом, более частыми клиническими рецидивами и большим числом повреждений магнитно-резонансных изображений (MRI) по сравнению с SMS для взрослых (AOMS), что оказывает значительное воздействие как на развитие инвалидности, так и на когнитивные результаты у затрагиваемых лиц. Управление ПОМС сопряжено с особыми проблемами, обусловленными уникальными потребностями педиатрических пациентов и ограниченным количеством методов лечения, позволяющих рег

Совпадение в аннотации оригинала
Pediatric-onset multiple sclerosis (POMS) refers to multiple sclerosis with onset before 18 years of age. It is characterized by a more infl … the United States (US) Food and Drug Administration (FDA) and three (fingolimod, teriflunomide, and dimethyl fumarate) by the European Medicines Agency (EMA) for use in youth with MS. However, observational evidence identifies use of almost all agents off-label in this population. This review provides a comprehensive overview of literature supporting the use of DMT …

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.

INTRODUCTION: Vaccination against the coronavirus disease 2019 (COVID-19) is recommended for patients with multiple sclerosis (MS), neuromye … owing vaccination. Facial sensory changes with a brainstem lesion developed in an MS patient taking dimethyl fumarate, while myelitis occurred in a MOGAD patient receiving azathioprine maintenance therapy. The first episode of optic neuritis occurred in a patient who was later diagnosed with MOGAD. CONCLUSIONS: Our study demonstrated a favorable safety profile wit …

"No association between disease modifying treatment and fatigue in multiple sclerosis".

BACKGROUND: Fatigue affects 60-90% of people with multiple sclerosis (MS). It reduces quality of life and the ability to work. The cause of … oietic stem cell transplantation. Moderate-efficacy drugs included interferons, glatiramer acetate, dimethyl fumarate, and teriflunomide. We included persons with relapsing MS only. RESULTS: Of 1142 patients, 80% had fatigue. Fifty-six percent of the patients were on DMTs (25% on moderate-efficacy treatment and 30% on high-efficacy treatment), 18% had discontinued …

The Impact of SARS-CoV-2 Infection in Unvaccinated Multiple Sclerosis Patients on Disease-Modifying Therapies.

OBJECTIVE: Disease-modifying therapies (DMTs) in multiple sclerosis (MS) may affect the course and outcome of COVID-19, but withholding them … od and natalizumab), and 13 were on other DMT treatments (alemtuzumab, cladribine, interferon-beta, dimethyl fumarate, and teriflunomide). 43/51 of these patients experienced mild COVID-19, not requiring hospitalization. None of the subjects experienced MS relapses during infection. Two patients on rituximab had a moderate course of the illness, which required hosp …

CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.

BACKGROUND: Several reports have been documented in possible association with the administration of different severe acute respiratory coron … red after receiving 3 doses of Corticosteroids. Common medications were Natalizumab, Teriflunomide, Dimethyl fumarate, and Rituximab. Also, Interferon beta 1-a was administered to one patient with severe symptoms of numbness. CONCLUSION: Our case series identifies the Sinopharm BBIBP-CorV and the AstraZeneca AZD1222 vaccines as potential triggers for CNS demyelina …